TiumBio Co., Ltd.

Acquired Hemophilia A Pipeline Expands with 10+ Novel Therapies in Development

6 days ago

• Global Acquired Hemophilia A pipeline comprises over 10 companies developing innovative therapies across various clinical stages, according to DelveInsight's 2025 report. • Recent clinical advances include promising results for rituximab as a potential first-line therapy and Pfizer's positive Phase 3 AFFINE trial results for giroctocogene fitelparvovec gene therapy. • Key pharmaceutical players including Novo Nordisk, Sanofi, Pfizer, and Belief Biomed are advancing treatments ranging from gene therapies to monoclonal antibodies targeting this rare autoimmune bleeding disorder.

TiumBio Doses First Patient in Phase 2 Trial of Oral Immuno-Oncology Drug TU2218

8 months ago

• TiumBio has dosed the first patient in a Phase 2 clinical trial of TU2218, an oral dual inhibitor targeting TGFR1 and VEGFR2. • The Phase 2a trial will evaluate TU2218 in combination with Keytruda for head and neck squamous cell carcinoma, biliary tract cancer and colorectal cancer. • Phase 1b trial data showed a 80% disease control rate when TU2218 was combined with Keytruda in advanced solid tumor patients.

Hemophilia A and B Pipeline Advances with Novel Therapies in Clinical Trials

8 months ago

• Several companies are actively developing novel therapies for Hemophilia A and B, with many in various phases of clinical trials, showing promise for improving treatment options. • TiumBio Co., Ltd. has submitted a Clinical Trial Application to initiate a Phase 1b investigation of TU7710, a new recombinant activated factor VII for hemophilia patients with inhibitors. • The FDA approved ALTUVIIIO (efanesoctocog alfa) in February 2023, a factor VIII replacement therapy for adults and children with Hemophilia A, for routine prophylaxis and on-demand treatment. • BioMarin received FDA approval for Roctavian in June 2023, a single-dose gene therapy for severe Hemophilia A, marking a significant advancement in treatment.